FDA Approves GABAPENTIN — Advagen Pharma Ltd
Advagen Pharma Ltd announced today that the FDA has approved the Abbreviated New Drug Application (ANDA077661) for gabapentin, the generic product currently marketed under the brand name GABAPENTIN. This approval is expected to significantly increase market competition for the oral version of the substance, potentially driving down prices and reshaping market share among neurology generic competitors.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed